Maximize Beta-Blockers Before Starting Ivabradine

Ivabradine (Corlanor, CORE-lah-nore) will be the first new drug approved for systolic heart failure in a decade.

It works by inhibiting the If or "funny" current in the sinoatrial node. This lowers heart rate...withOUT causing a drop in blood pressure.

Ivabradine prevents 1 in 25 patients from being hospitalized over 2 years...when ADDED to standard therapy including an ACEI or ARB, beta-blocker, and aldosterone antagonist. But it DOESN'T reduce overall mortality.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals